Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference
Retrieved on:
Wednesday, August 11, 2021
Autoimmunity, Cleveland BioLabs, Homeostasis, CEO, Patient, Union, Annual report, Exercise, Immune system, Antibody, TLR9, Conference, Risk, Kingdom, Meeting, Business, European Union, Virus, Fibromyalgia, Cancer, TLR5, COVID-19, Research, Crohn's disease, Coronavirus, Budget, Cleveland, History, SEC, NASDAQ, Radiation Sickness, TLR4, Multiple sclerosis, Growth, Liberty University School of Law, Pancreatic cancer, Pharmaceutical industry
Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on August 11, 2021.
Key Points:
- Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on August 11, 2021.
- Specifically, Cytocom has several clinical-stage development programs for Crohn's disease, pancreatic cancer, COVID-19 in addition to expansion to fibromyalgia and multiple sclerosis.
- While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control.
- The forward-looking statements included in this press release are made only as of the date hereof.